Lexeo Therapeutics, Inc. Common Stock
Lexeo Therapeutics, Inc. Common Stock (LXEO) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · LXEO · as of Sep 30, 2025
Ownership Breakdown
112
Institutional Holders
▲ 21 vs Q2
$327.72M
Total Inst. Value
▲ $157.72M vs Q2
78.52M
Shares Outstanding
freeFloat 60.50%
49.36M
13F Shares Held
▲ 7.09M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
LXEO largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
JANUS HENDERSON GROUP PLC biological products, (no diagnostic substances) | 6.11M | 10.01% | 10.01% | $40.49B | Nov 14, 2025 | ▲ 2.42M |
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. biological products, (no diagnostic substances) | 4.42M | 7.26% | 7.26% | $29.38B | Nov 14, 2025 | — held |
BALYASNY ASSET MANAGEMENT L.P. biological products, (no diagnostic substances) | 3.91M | 6.42% | 6.42% | $25.99B | Nov 14, 2025 | ▼ 95.3K |
AFFINITY ASSET ADVISORS, LLC biological products, (no diagnostic substances) | 3.87M | 6.35% | 6.35% | $25.70B | Nov 13, 2025 | ▲ 281.2K |
CITADEL ADVISORS LLC biological products, (no diagnostic substances) | 3.72M | 6.10% | 6.10% | $24.69B | Nov 14, 2025 | ▲ 111.1K |
VESTAL POINT CAPITAL, LP biological products, (no diagnostic substances) | 3.25M | 5.33% | 5.33% | $21.58B | Nov 14, 2025 | ▲ 21.8K |
WOODLINE PARTNERS LP biological products, (no diagnostic substances) | 2.57M | 4.22% | 4.22% | $17.08B | Nov 14, 2025 | — held |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 2.31M | 3.79% | 3.79% | $15.36B | Nov 14, 2025 | ▼ 522.6K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 2.23M | 3.65% | 3.65% | $14.78B | Nov 7, 2025 | ▲ 223.4K |
BLACKROCK, INC. biological products, (no diagnostic substances) | 2.17M | 3.56% | 3.56% | $14.42B | Nov 12, 2025 | ▲ 343.1K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
27
Increased
+7.63M shares6
New Positions
first time holders9
Decreased
−687.9K shares0
Sold Out
fully exitedNet shares change (top 50)
+6.95M
+7.63M / −687.9K
Net new holders
+24
6 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
LXEO insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
1
Buy transactions
3
Sell transactions
0.33
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Otero Jose Manuel Chief Operating Officer | May 18, 2026 | Sale | 1,302 | $5.07 | $6.6K | 130.1K | Form 4 ↗ |
Townsend Richard Nolan Chief Executive Officer | May 18, 2026 | Sale | 3,342 | $5.06 | $16.9K | 336.8K | Form 4 ↗ |
Sepp-Lorenzino Laura director | Apr 28, 2026 | Award | 50,000 | $5.81 | $290.5K | 50.0K | Form 4 ↗ |
Townsend Richard Nolan Chief Executive Officer | Apr 6, 2026 | Sale | 55,000 | $5.69 | $313.1K | 340.1K | Form 4 ↗ |
Townsend Richard Nolan Chief Executive Officer | Mar 13, 2026 | Award | 2,623 | $2.64 | $6.9K | 395.1K | Form 4 ↗ |
Otero Jose Manuel Chief Operating Officer | Mar 13, 2026 | Award | 5,930 | $2.64 | $15.7K | 131.4K | Form 4 ↗ |
Otero Jose Manuel Chief Operating Officer | Feb 18, 2026 | Sale | 3,016 | $6.40 | $19.3K | 125.5K | Form 4 ↗ |
Townsend Richard Nolan Chief Executive Officer | Feb 18, 2026 | Sale | 10,173 | $6.38 | $64.9K | 392.5K | Form 4 ↗ |
Otero Jose Manuel Chief Operating Officer | Nov 18, 2025 | Sale | 721 | $9.27 | $6.7K | 63.5K | Form 4 ↗ |
Bhalla Narinder Pal Chief Medical Officer | Feb 13, 2026 | Award | 297,000 | $6.31 | $1.87M | 297.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Lexeo Therapeutics, Inc. Common Stock (LXEO) is primarily owned by institutional investors, who hold approximately 62.9% of total shares outstanding. Company insiders own approximately 39.50%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Lexeo Therapeutics, Inc. Common Stock is JANUS HENDERSON GROUP PLC, holding approximately 6.11 million shares — equal to 10.01% of outstanding shares — as of September 30, 2025.
A total of 112 institutional investors currently hold LXEO stock, with a combined institutional value of approximately $327,717,307 as of the most recent 13F filing period.
Frequently asked questions
LXEO ownershipLexeo Therapeutics, Inc. Common Stock (LXEO) is primarily owned by institutional investors, who hold approximately 62.9% of shares. The largest shareholder is JANUS HENDERSON GROUP PLC with a 10.01% stake. Company insiders hold 39.50%. Data sourced from SEC Form 13F as of September 30, 2025.